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The goal in type 1 diabetes (T1D) therapy is to maintain optimal glycemic control under
any circumstance. Diabetes technology is in continuous development to achieve this
goal. The most advanced Food and Drug Administration- and European Medicines
Agency-approved devices are hybrid closed-loop (HCL) systems, which deliver insulin
subcutaneously in response to glucose levels according to an automated algorithm.
T1D is frequently encountered in the perioperative period. The latest international
guidelines for the management of children with diabetes undergoing surgery include
specific adjustments to the patient’s insulin therapy, hourly blood glucose monitoring, and
intravenous (IV) insulin infusion. However, these guidelines were published while the HCL
systems were still marginal. We present a case of a 9-year-old boy with long-standing
T1D, under HCL system therapy for the last 9 months, and needing surgery for an
appendectomy.We agreedwith the family, the surgical team, and the anesthesiologists to
continue HCL insulin infusion, without further adjustments, hourly blood glucose checks
or IV insulin, while monitoring closely. The HCL system was able to keep glycemia within
range for the total duration of the overnight fast, the surgery, and the initial recovery,
without any external intervention or correction bolus. This is, to the best of our knowledge,
the first reported pediatric case to undergo major surgery using a HCL system, and the
results were absolutely satisfactory for the patient, his family, and the medical team. We
believe that technology is ripe enough to advocate for a “take your pump to surgery”
message, minimizing the impact and our interventions. The medical team may discuss
this possibility with the family and patients.
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INTRODUCTION
As diabetes technologies evolve toward the artificial pancreas pursuing to achieve the maintenance
of the patient’s glycemia within normal range, the number of children with type 1 diabetes (T1D)
using these technologies is increasing. Since T1D is a relatively common condition, we often find
children with T1D presenting for procedures or surgery requiring fasting and anesthesia (1). Indeed
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the International Society for Pediatric and Adolescent Diabetes
published the clinical practice consensus guidelines for the
management of children and adolescents with diabetes requiring
surgery in 2018, which have been endorsed in 2019 by the
recommendations proposed by a large tertiary care with a broad
experience in managing such patients in a surgical setting (1, 2).
The general recommendation for surgeries in which anesthesia
is predicted to last for more than 2 h or is likely to cause
post-operative nausea, inability to feed, or vomiting include
receiving both dextrose and insulin via intravenous (IV) infusion,
hourly blood glucose (BG) checks, and specific adjustments in
the patient’s insulin schedule. These recommendations, however,
focus on patients using continuous subcutaneous insulin infusion
(CSII) with predicted low glucose suspend algorithm (also known
as sensor-augmented CSII), but not to themost advanced devices.
Technologies evolve at a faster pace than scientific
recommendations for every aspect of diabetes care. The
latest European Medicines Agency- and Food and Drug
Administration-approved insulin pumps are the hybrid closed-
loop (HCL) systems, a leap toward the artificial pancreas,
which are already being used by an increasing number of
patients, both with T1D and T2D. The HCL systems basically
administer subcutaneous insulin in the form of micro-boluses
according to an automated algorithm in response to glucose
levels as measured by a glucose continuous monitor (3). The
HCL systems are programmed by the physician initially to a
certain insulin administration schedule. During the first weeks
of use, this system functions as a sensor-augmented CSII and
continuously collects information on the patients’ response to
the preprogrammed insulin. It then applies artificial intelligence
algorithms to adapt to each individual’s response. After a period
of deep learning (minimum of 2 weeks), the pump may be set
to work in “auto-mode,” that is, responding automatically to
glucose levels without a fixed basal rate. As a back-up emergency
plan, in the event of temporary CGM signal interruption or loss,
the HCL system keeps running according to the initial program
(manual mode) as a conventional CSII. When in auto-mode, the
HCL systems have proven to obtain enhanced glycemic control
and reduced variability (improved time in glycemic target range),
fewer hypoglycemic episodes, and greater patient satisfaction
(4, 5).
We present a case of a boy with long-standing T1D,
using HCL system therapy for months with good results, who
needed surgery for an appendectomy. Since there are still no
recommendations for the use of these devices in the perioperative
period, we agreed with the patient, the family, and the surgical
and anesthesiology team to continue with the HCL system
throughout the whole procedure under the strict supervision of
pediatric endocrinologists.
PATIENT PRESENTATION
A 9-year-and-9-month-old boy with uncomplicated
autoimmune T1D since the age of 11 months, 46.3 kg of
weight, and with HbA1c of 7% in his last consultation 2 months
before the event, was admitted to the emergency room with
abdominal pain migrating to the right lower quadrant, anorexia,
and nausea during the last 24–48 h. The blood tests showed
8,620/mm3 white blood cell count with 60% neutrophils and
10.5 mg/L C-reactive protein. There were no signs of diabetic
ketoacidosis, and the glucose levels were optimal, with negative
B-hydroxybutyrate [pediatric appendicitis score (6) = 7].
Abdominal ultrasounds confirmed an increased appendix
thickness (8mm) and diagnosis of uncomplicated appendicitis.
The patient had used a HCL system (Medtronic 670G R© in
auto-mode) for 9 months, had improved metabolic control since
its use (estimated HbA1c 7.3% and average blood glucose 162 ±
68 mg/dl; Figure 1), felt very comfortable with the device, and
both the patient and the parents were reluctant to interrupt it (the
system’s program details are shown in Supplementary Table 1).
His ratios and sensitivities had been programmed in his last visit
according to the patient’s glycemic response to prandial insulin,
but this does not affect basal insulin administration since the
basal rates are not altered by this program when the system runs
in auto-mode. According to data extracted from the patient’s
account on the web managing system of the pump, at 2 days
prior to the symptoms, the system’s basal delivery had been 20.6
and 19.2 IU/day, respectively. Since the first symptoms presented,
a remarkable increase in these needs were noted, with a basal
delivery rate of 26.7 and 30.7 IU/day, respectively.
Upon diagnosis, the patient was started on intravenous
cefoxitin at 40 mg/kg and acetaminophen. We then faced an
overnight fast since surgery was programmed for the next
morning. The parents expressed their desire to continue with
the HCL system if it were possible throughout the procedure.
Since there are still no recommendations for this devices, we first
checked that the CGM had still 72 h left of expected life and that
the pump had enough insulin for at least 36more hours. The CSII
was inserted at the left gluteus and the CGM on the left arm;
thus, neither would interfere with the surgical field or with the
electric scalpel.
Since all prerequisites were fulfilled and the family gave
written consent, the pediatric endocrinology team agreed to let
the system run in auto-mode, under close clinical monitoring.
The pump’s basal rate in case the system switched to “manual
mode” due to CGM loss or malfunction was adjusted to 50%
of the usual dose as recommended (7). We decided to start
an IV infusion of 5% dextrose, with 150 mEq/L of sodium
and 20 mEq/L of potassium to prevent ketosis (see Table 1 for
preparation instructions), but avoided IV insulin and checked
the system’s behavior overnight. Indeed capillary ketones were
always under 0.3 (we checked every 4 h), and glucose levels
were always in the 80-180 mg/dl (4.44–9.99 mmol/L) range. The
system infused a total of 82 micro-boluses of 0.11 IU of insulin on
average (range, 0.03–0.13; Figure 2—overnight fast). The system
also spent a total time of 1 h and 15min without administering
any micro-bolus.
Having analyzed the system’s performance, we agreed with the
anesthesiologist and the surgeons to keep the system running
automatically throughout the procedure, having a clear plan
for CSII interruption and insulin IV infusion if necessary. A
member of the pediatric endocrinology team was available at
all times.
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FIGURE 1 | Graph showing an overview of the patient’s glycemic control the week prior to the episode. Directly taken from the patient’s personal record on the hybrid
closed-loop system’s manufacturer’s site.
TABLE 1 | Summary of recommendations on the use of the hybrid closed-loop
system during the perioperative period.
Pre-surgery - Check if the pump battery is charged
- Check if the CGM has at least 72 h of expected lifetime and
the sensor is properly calibrated
- Check if there is enough insulin at the reservoir for at least
36 h
- Check if the transmitter is successfully communicating with
the pump
- Check if the location of neither the sensor nor the catheter
may interfere with the surgery field or the electric scalpel
- Start infusion of 5% IV dextrose, with 150 mEq/L sodium and
20 mEq/L potassium (prepare by adding 22ml of 20% NaCl
and 5ml of 2M KCl to every 500ml of 5% dextrose)
- Check capillary ketones every 4 h
- Check if the suspension before low and high management
settings is “ON”
- Check if the high, low, and before alerts are “ON”
- Audio mode is “ON”
- Airplane mode is “OFF”
- Check if the insulin bolus is not being delivered.
- Check if the glucose level is within optimal range.
During surgery - Follow the indications on the pump
- Should glucose levels rise over 200 mg/dl or fall below 70
mg/dl on the systems screen, check the capillary blood
glucose levels with a glucose strip.
- Stop pump infusion and start IV insulin perfusion if the glucose
levels rise over 250 mg/dl (after checking with capillary blood
glucose) despite pump correction bolus
- Consider changing the dextrose concentration in perfusion
to 10% or administering a bolus of 10% dextrose IV (10
ml/kg) if the glucose level falls under 70 mg/dl, as checked in
a capillary or venous sample
CGM, continuous glucose monitor; IV, intravenous.
The laparoscopic appendectomy took∼2.5 h since the patient
was sent to the surgery room until he left it, and it was
performed without relevant incidences. Pathologic confirmation
of acute uncomplicated appendicitis was obtained. The system
automatically delivered 16 micro-boluses during the procedure.
The mean dose of these boluses was 0.089 IU of insulin (range,
0.05–0.13), and the glucose levels were always within range
(Figure 2—laparoscopic appendectomy). Taking together the
overnight fast and the surgery, the system infused 20.3 IU/day
of insulin, in contrast with the 30.7 IU/day it had infused the
day before.
Right before oral tolerance was started, the patient’s mother
noticed that the glucose levels tended to drop and programmed,
by her own initiative, a temporary increase in the glucose
target to 140 mg/dl. We then decided to begin oral tolerance
(3 h post-surgery; Figure 2), resulting in a hyperglycemic peak
(maximum, 280 mg/dl) since no prandial insulin bolus had been
administered, and dextrose fluid had not been discontinued.
The patient was finally discharged 24 h after surgery without
incidence and with the HCL system functioning uninterruptedly.
The basal insulin infusion at 48 h after surgery dropped down to
19.0 and 15.5 IU/day.
DISCUSSION
To the best of our knowledge, we present the first pediatric
case of a patient with T1D undergoing a major surgery
with uninterrupted use of an HCL system running in auto-
mode. Our results were optimal in terms of glycemic control,
with no external or additional adjustments, as well as the
patient’s and family’s satisfaction. This approach allowed for a
minimally invasive and less disruptive management, performed
in agreement with the family and surgical team and with the
pediatric endocrinologist’s commitment to closely supervise the
procedure throughout. This was necessary since the most recent
clinical guidelines and recommendations for the management
of patients with diabetes in CSII therapy undergoing surgery
or anesthesia-requiring procedures focus on conventional CSII
and do not take into account the more advanced HCL systems
(1, 2). A previous report on an adult patient with T1D undergoing
metabolic surgery (sleeve gastrectomy) focused more on the
results of the surgery itself rather than the perioperative period
but helped us in the decision to program the 50% reduction in
the manual-mode basal insulin delivery rates (7).
Insulin doses administered as micro-boluses automatically by
the pump in response to the patient’s CGM were 0.024 IU/kg/h
during fasting and 0.015 UI/kg/h during appendectomy. To
achieve such low-dose infusion with IV insulin, we would have
very likely needed to check the patient’s BG hourly and make
adjustments to the insulin and dextrose infusions, which is how
it is recommended to date.
Alternatively, our approach specifically allowed us to avoid
interrupting the patient’s usual therapy, hourly capillary BG
testing, the use of alternative basal rate, and the need for
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FIGURE 2 | Overview of the glucose levels along the episode. Arrows point to the following events: (1) admission at the emergency room, (2) overnight fast, (3 and 4)
laparoscopic appendectomy, and (5) initiating oral tolerance. Open circles reflect blood glucose calibrations.
intravenous insulin infusion. Continuing the patient’s usual
therapy was less disruptive and invasive and resulted in the
patient’s, family’s, and medical team’s satisfaction.
Since diabetes technology advances at an accelerated pace,
it seems very unlikely that we have time to develop well-
dimensioned clinical trials to test every technical step forward in
every aspect of diabetes care, especially how to face unexpected
events such as urgent surgeries. We believe that this experience
provides a starting point for a novel approach to perioperative
management of children with T1D and advocate for a “take
your pump to surgery” message that could be contemplated with
patients and family and considered by surgical teams, under close
supervision by pediatric endocrinologists. We provide a table of
recommendations based on previous recommendations (1, 2),
reports (7), and our own experience (Table 1).
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